Docetaxel in Non Small Cell Lung Cancer (NSCLC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00263016|
Recruitment Status : Terminated (Slow recruitment)
First Posted : December 7, 2005
Last Update Posted : March 20, 2008
- To compare the tumour response rate of combination chemotherapy irinotecan/cisplatin (IC) versus docetaxel/cisplatin (DC) in advanced NSCLC patients who responded to 3 courses of docetaxel/cisplatin.
Secondary Objectives :
- To compare the time to progression after chemotherapy treatment between the IC and DC arms of treatment.
- To compare the toxicity profile of the IC and DC arms of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Non-Small-Cell Lung||Drug: Docetaxel||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Pilot Study of Combination of Irinotecan and Cisplatin in Docetaxel/Cisplatin-Responsive Advanced Non-Small Cell Lung Cancer|
|Study Start Date :||May 2005|
- Tumour response rate
- Survival at 1 year
- Time to progression
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00263016
|Hong Kong, Hong Kong|
|Study Director:||Iris CHAN, MD||Sanofi|